

The Immunoassay Handbook

SECOND EDITION



Edited by
David Wild

CONTENTS

Contributors	xx
Preface	xxiv
Acknowledgements	xxvii
Foreword	xxviii

PART 1 PRINCIPLES

1	Introduction to Immunoassay Principles <i>Chris Davies</i>	3
	Immunoassay for beginners	3
	Kinetics of antibody-antigen interactions	5
	Immunoassay design	11
	Competitive (reagent limited) assays	13
	Single-site immunometric assays	14
	Two-site immunometric assays (reagent excess)	14
	Determinants of assay sensitivity	15
	Detection and quantification of antibodies	30
	Special considerations for solid-phase immunoassays	32
	Comparison of experimental and theoretical immunoassay performance	37
2	Anti-complex and Selective Antibody Immunometric Assays for Small Molecules <i>Colin H. Self and Larry A. Winger</i>	41
	Introduction	41
	The anti-complex assay	41
	Enhanced specificity	42
	The multiple binding assay	44
	The selective antibody immunometric assay	44
	Conclusions	44
3	Ambient Analyte Assay <i>Roger Ekins</i>	46
	Introduction	46
	Basic theoretical principles	47
	Applications of the ambient analyte assay principle	48
	Microspot assays	49
	Free (non-protein bound) hormone immunoassays	57
	Other applications of the principle	59
	Summary and conclusion	59
4	Free Analyte Immunoassay <i>Nic D. Christofides</i>	61
	Basic principles governing the free hormone concentration	61
	Calculation of free analyte concentration	61
	Spreadsheet for calculation of free analyte concentration	62
	Effect of serum proteins on free analyte concentration	65
	<i>In vitro</i> measurement of free analyte concentration	66
	Direct equilibrium dialysis	66
	Immunoassays for free analytes	68
	Tests of validity (accuracy)	74
	Concluding remarks	76
5	Concepts <i>Chris Davies</i>	78
	Assay concepts	78
	Assay sensitivity	78
	Accuracy and bias	78

	Precision and imprecision	79
	Cross-reactivity	83
	Interference	86
	Recovery	89
	Dilution	90
	Correlation and method comparison	90
	Assay drift	94
	Clinical concepts	95
	Diagnosis	96
	Reference interval	96
	Clinical sensitivity and specificity,	98
	Positive and negative predictive values	100
	Prevalence and clinical utility	100
	Likelihood ratio	101
	Continuous measurement, ROC curves	102
	Confidence interval analysis of clinical performance	103
	Probabilistic interpretation of test results	103
	Analytical goals	104
	Summary	107
6	Immunoassay Development in the <i>in vitro</i> Diagnostic Industry	
	<i>Doug Brandt and Steve Figard</i>	111
	Assay design overview	111
	The needs of the customer	111
	The capability of the technology	112
	The requirements for consistent manufacturing	112
	Experimental design in immunoassay development	112
	Preamble	112
	The process in overview	113
	The problems assuaged by DOE	113
	The particulars	113
	Four key assay design principles	115
	Plan first	115
	Think from a theoretical perspective	115
	Simplify the approach	116
	Establish specifications before starting	117
	Concluding comments	117
7	Antibodies <i>Eryl Liddell</i>	118
	Introduction	118
	Antibody structure	118
	The antibody response <i>in vivo</i>	119
	Antibody diversity	121
	Immunization	121
	Immunogen	121
	Polyclonal antisera	122
	Purification of antisera	123
	Monoclonal antibodies	123
	Immune lymphocyte	124
	Myeloma cell lines	125
	Cell fusion	126
	Hybrid selection	126
	Antibody screening tests	126
	Cloning	127
	Storage and propagation	127
	Human monoclonal antibodies	128
	Purification of monoclonal antibodies	128

Antibody fragments	128
Bispecific antibodies	129
Chimeric and humanized antibodies	130
Recombinant antibodies	130
Recombinant phage antibody library construction	130
Selection of specific phage antibodies	133
Altering antibody characteristics	133
Synthetic recombinant antibodies	133
Bivalent and bispecific genetically engineered antibodies	134
Antibody conjugates and fusion proteins in diagnostics	134
Polyclonal, monoclonal or recombinant?	134
8 Standardization and Calibration <i>David Wild</i>	140
Standardization	140
The role of external quality assessment (proficiency testing) schemes	140
International standards	141
Definitive and reference methods	142
Other reference materials	143
Heterogeneity of standard material	143
Method-related causes of standardization differences	143
Special considerations for assay of antibodies	145
Calibration	146
Analyte	146
International standards	146
Secondary standards	146
Calibrators	146
Standard and calibrator matrices	147
Reduced and stored calibration curves	147
Recovery and dilution	148
Separation Systems <i>David Wild</i>	149
Liquid-phase separations	149
Electrophoresis	149
Gel filtration	149
Dextran-coated charcoal	150
Precipitation by salts, organic solvents and polyethylene glycol (PEG)	150
Double (second) antibody precipitation	150
PEG-assisted second antibody precipitation	150
Aspiration and decantation methods	150
Surface-coated solid-phases	151
General principles of protein binding to plastic surfaces	151
Covalent attachment of proteins to solid-phases	154
Glass and plastic particles	154
Magnetizable particles	155
Tubes, wells and microtitration plates	155
Beads	155
Common solid-phase	156
Membrane filtration	156
Immunochromatography	156
Western blot	156
Washing	157
Competitive assays	157
Immunometric assays	157
Removal of interfering substances	157
The mechanics of washing	157

10	Signal Generation and Detection Systems (Excluding Homogeneous Assays)	
	<i>Larry Kricka and David Wild</i>	159
	Radioactive labels	159
	Radioactivity measurement	159
	Preparation of radioactive tracers	160
	Enzyme labels	161
	Colorimetry	162
	Fluorometry	162
	Chemiluminescence	165
	Enhanced chemiluminescence	165
	Direct fluorescence	165
	Long wavelength fluorescence	166
	Time-resolved fluorescence	167
	Direct chemiluminescence	168
	Bioluminescence	170
	Phosphorescence	171
	Microparticle labels	171
	Streptavidin/avidin-biotin	171
	Protein A	173
	Amplification strategies	173
	Multiple analytes and miniaturization	175
11	Homogeneous Immunoassays <i>Edwin F. Ullman</i>	177
	Introduction	177
	Particle agglutination	177
	Erythrocytes and latex	177
	Gold sols	178
	Lysis immunoassays	179
	Spin immunoassays	180
	Fluorescent labels	180
	Fluorescent polarization immunoassay (FPIA)	180
	Fluorescent resonance energy transfer (FRET)	182
	Fluorescence protection assays	183
	Fluorescence fluctuation	184
	Enzyme immunoassays	185
	Enzyme-multiplied immunoassay technique (EMIT®)	185
	Charge induced enzyme activation	187
	Enzyme channeling	187
	Enzyme effector immunoassays	188
	Substrate-linked fluorescence immunoassay (SLFIA)	189
	Enzyme cofactor immunoassay	189
	Enzyme inhibitor immunoassay	190
	Enzyme complementation immunoassay	190
	Isotopic labels	191
	Scintillation proximity assay (SPA)	191
	Electroactive labels	192
	Electrochemical detection	192
	Electrochemiluminescence (ECL)	192
	Oxygen channeling immunoassays	192
	Luminescent oxygen channeling immunoassay (LOCI)	192
	Conclusion	194
12	Calibration Curve-fitting <i>Barry Nix and David Wild</i>	198
	Introduction	198
	Dose-response meter	198
	Response-error relationship	198
	Homo- and heteroscedasticity	198

Linearizing transformations	198
Normalizing transformations	198
Outliers	199
Empirical and theoretical curve-fitting methods	199
Least-squares fitting procedure	199
Weighted least-squares procedure	199
Precision profiles	200
Examples of calibration curve-fitting methods	200
Hand-plots	201
Linear interpolation	201
Spline Fits	202
Polynomial regression	202
Logit-log and four-parameter log-logistic methods	202
Five-parameter log-logistic	205
Four-parameter Law of Mass Action	205
Monitoring the quality of curve-fitting	205
Stored calibration curves, factory master curves and adjusters	205
Master calibration curve	206
Adjusters	206
Modeling calibration curve changes over shelf-life	208
Use of electronic data transmission	208
Summary	208
Suitable calibration curve-fit software	209
Conjugation Methods <i>Alastair H. Dent</i>	211
Categories of conjugates employed in immunoassay	211
Protein-protein coupling	212
Functional chemistry of proteins	212
Categories of protein-protein coupling reaction	214
Common protein-protein coupling methods	215
Genetic engineering approaches to protein conjugation	218
Protein-small molecule coupling	219
Introduction	219
Common protein-small molecule coupling methods	221
Purification of conjugates	223
Chromatographic approaches to conjugate purification	223
Other approaches to conjugate purification	226
Characterization of conjugates	226
Conclusion	227
Immunological Biosensors <i>P. Gordon Malan</i>	229
An overview	229
Amperometric sensors	230
Potentiometric sensors	231
Mass-detection sensors	232
Optical sensors	233
Fluorescence evanescent-wave sensors	234
Fluorescence capillary-fill device (FCFD)	234
Surface plasmon resonance (SPR) sensors	235
Fluorescence-enhanced SPR sensors	237
Integrated optics sensors	237
Holographic sensors	237
Conclusion	237

PART 2 PRODUCT TECHNOLOGY

15	Introduction to Product Technology <i>David Wild</i>	243
	Immunoassay product technologies	243
	Use of fluorescence-labeled antibodies	243
	Agglutination assays	243
	Radioimmunoassay (RIA) and immunoradiometric assay (IRMA)	244
	Heterogeneous enzyme-immunoassay (EIA)	244
	Homogeneous enzyme-immunoassay	244
	Automated homogeneous batch analyzer	244
	Automated heterogeneous batch analyzer	244
	Nonradioactive systems with increased sensitivity	245
	Semi-automated systems	245
	Automated dual technology batch analyzer	245
	Automated multianalyte batch analyzers	245
	Random-access analyzers with bulk reagent packs	245
	Unitized random-access systems	246
	Clinical chemistry analyzers	246
	Near-patient tests	247
	Home-use tests	247
	Other applications	247
	Future developments	247
16	Market Trends <i>David Huckle and David Wild</i>	248
	Immunoassay market status	248
	Established trends	249
	Market drivers	249
	Advances in technology	250
	New analytes	252
	The future of the immunodiagnostics business	253
	Application of marketing theory to immunodiagnostics	253
	Future market requirements	254
	Changes in the customer base	256
	Potential impact of new technologies	257
	New analytes	258
	The role of the clinical laboratory	259
	Conclusion	259
	Summary of likely trends in immunodiagnostics and related products	260
17	Choosing an Automated Immunoassay System <i>Lori J. Sokoll and Daniel W. Chan</i>	261
	Defining automation goals	261
	Sources of information	261
	Considerations and criteria	262
	Laboratory environment considerations	262
	Test menu considerations	263
	Technical and clinical considerations	263
	Financial considerations	263
	Operational considerations	264
	Summary	264
18	Automated System Features <i>Alain Truchaud, Tanguy Le Neel, Murielle Cazaubiel, Bernard Capolaghi and Jean-Pierre Yvert</i>	266
	Introduction	266
	Specific requirements of immunoassays	266
	Concepts in immunoassay automation: workstations vs. integrated systems	267
	Reagent features	268

	Infrequent calibration	268
	Traceability	268
	Multiselective testing and continuous operation	268
	Sample features	268
	Sample integrity	268
	Biosafety	268
	Dilution and reflex testing	268
	Stat testing	268
	Incubation and washing	269
	Measurement	269
	Total quality management/traceability	269
	Maintenance	269
	Ergonomics	269
	Integrated automation	269
	Conclusion	270
19	Over-the-counter Pregnancy Test Kits <i>Michael J. Wheeler</i>	271
	Introduction	271
	Evaluation of OTC kits	272
	User preferences	273
	Factors affecting the measurement of HCG in urine	275
	Summary	276
20	Fluorescence Microscopy: Micro Trak[®] <i>Tom Houts</i>	278
21	Automated Batch Analyzers: Imx[®] <i>Kent Ford</i>	280
22	Automated Batch Analyzers: Stratus[®] immunoassay Systems <i>W. N. Mclellan and David Plaut</i>	287
23	Bulk Reagent Random-Access Analyzers: UniCAP[®] 100 <i>Gareth Evans and Mats Rilvén</i>	293
24	Automated Panel Analyzers PRISM[™] <i>Dinesh Shah and Jim Stewart</i>	297
25	Unitized Reagent Random-Access Analysers: IMMULITE[®] <i>Arthur L. Babson</i>	304
26	Unitized Reagent Random-Access Analyzers: OPUS[®] and OPUS[®] PLUS <i>H. Joseph Crowley and Michael A. Bauduin Revised by Robert J. King and W. N. Mclellan</i>	308
27	Bulk Reagent Random-Access Analyzers: ETS[®] Plus System (Emit[®]) <i>Joan Centofanti and Tom Houts</i>	313
28	Bulk Reagent Random-Access Analyzers: ACS:180[®] SE <i>Richard Dudley</i>	316
29	Bulk Reagent Random-Access Analyzers: Access[®] immunoassay System <i>Rosemary Willett</i>	320
30	Bulk Reagent Random-Access Analyzers: AxSYM[®] <i>Theresa Donahoe</i>	329
31	Bulk Reagent Random-Access Analyzers: Immuno 1[™] <i>David A. Moran</i>	334
32	Bulk Reagent Random-Access Analyzers: Elecsys[™] Immunoassay Systems <i>Mary Beth Myers</i>	341

33	Bulk Reagent Random-Access Analyzers: Vitros® ECI <i>David Wild</i>	347
34	Bulk Reagent Random-Access Analyzers: IMMULITE® 2000 <i>Arthur L. Babson</i>	354
35	Bulk Reagent Random-Access Analyzers: ADVIA® Centaur™ <i>Laura Taylor</i>	359
36	Bulk Reagent Random-Access Analyzers: ARCHITECT™ /2000™ Analyzer <i>Frank A. Quinn</i>	363
37	Bulk Reagent Random-Access Analyzers: KRYPTOR™ <i>Brian E. Hickey</i>	368
38	Clinical Chemistry Analyzers: CEDIA® <i>William A. Coty</i>	373
39	Clinical Chemistry Analyzers: VITROS™ Immuno-Rate Assays <i>Susan J. Danielson and David A. Hilborn</i>	377
40	Near-Patient Tests: Testpack® Plus <i>John Bodner</i>	382
41	Near-Patient Tests: Triage® Cardiac System <i>Kenneth F. Buechler</i>	385
42	Near-Patient Tests: Optical Immunoassay <i>Lyndal Hesterberg</i>	390
43	Near-Patient Tests: Trop T™ Sensitive, CARDIAC T® Quantitive and CARDIAC M™ Rapid Assays <i>Jim Neher and Dale Knight</i>	395
44	Near-Patient Tests: Stratus® CS STAT Fluorometric Analyzer <i>W. N. McClellan and D. Plaut</i>	399
45	Over-the-counter Tests: Clearblue One Step™, Clearplan One Step™ and Clearview™ <i>Keith May</i>	403
46	Over-the-counter Tests: Persona™ <i>Keith May</i>	406

PART 3 LABORATORY MANAGEMENT

47	Subject Preparation, Sample Collection and Handling <i>Colin Wilde</i>	411
	Subject state and preparation	411
	Stress	411
	Exercise	411
	Food and drink	411
	Posture	412
	Medical procedures	412
	Drugs	412
	Pregnancy	413
	Age	413
	Race	413
	Timing	413
	Biological rhythms	413
	Dynamic tests	414
	Pathological changes	414
	Nonthyroidal illness †	414
	Therapeutic drug monitoring	414
	Blood collection by venepuncture	414

Precautions relating to the patient	414
Blood collection	415
Preparation of serum	416
Preparation of plasma	416
Whole blood	416
Interference by tube and stopper components	417
Interference	417
Precautions	417
The use of serum separations	417
Characteristics of separators	417
Interference	418
Other additives	418
Hemolysis	418
Collection of blood by skin puncture	418
Skin puncture sites	418
Collection into capillary tubes	419
Urine collection	419
Containers	419
Preservative	419
Types of collection	419
Instructions	419
Sample handling	419
Saliva	420
Procedures for sampling saliva	420
Special precautions	420
Cerebrospinal fluid	421
Formation of cerebrospinal fluid	421
Collection of CSF	421
Amniotic fluid	421
Collection of amniotic fluid	421
Amniocentesis	421
Special precautions	421
Sweat	422
Semen	422
Hair	422
Milk	422
Storage and transportation	422
Conclusions	422
48 Laboratory Quality Assurance <i>Pierre Blockx and Manuella Martin</i>	424
Staff selection and training	424
Fixed volume pipettes	425
Repeating pipettes	425
Semiautomated instruments	425
Manual dilutions	425
Equipment maintenance and testing	426
Laboratory water	427
Water purification methods	427
Water purity measurement	427
Recommended water quality	428
Sample control	428
Sample collection	428
Centrifugation	428
Storage	428
Reagent and control preparation	428
Assay quality control	429
Within-assay precision	429

	Between-assay precision	429
	Internal QC programs	430
	QC software on automated analyzers	434
	New generation QC software programs	434
	QC parameters other than controls	435
	QC in infectious disease tests	437
	External quality control schemes	437
	Point-of-care tests	438
49	Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) <i>Fred D. Lasky</i>	440
	Introduction	440
	Test complexity	441
	Waived	441
	Moderate complexity	441
	High complexity	441
	Test categorization criteria	441
	Quality control	442
	Proficiency testing	442
	Quality assurance	445
	The impact of CLIA	445
50	Point-of-care Testing <i>James H. Nichols</i>	448
	Delivery options	448
	Terminology	448
	Sites	448
	Operators	449
	Menu	449
	Economics	449
	Clinical outcome	451
	Quality assurance	452
	Components of good laboratory practice	452
	Regulations	452
	Data management	454
	Practical management	454
	Technical validation	454
	Quality control	455
	Administration	456
	Summary	456
51	Immunoassay Troubleshooting Guide <i>David Wild</i>	458
	Instructions	458
	Troubleshooting guide	459
	Control bias – consistent change in values from one period of time to another (or from one reagent lot to another)	459
	Gradual change in control values (not consistent change at one time or with change in reagent lot)	460
	Commercial controls consistently biased from target mean (no change in values across same lot of controls)	461
	Bias in proficiency testing (external quality assessment) scheme from other users of the same assay	462
	Bias in proficiency testing (external quality assessment) scheme of one method from all-laboratory mean or reference method	464
	Poor within-assay precision	465
	Poor between-assay precision or individual control failure	466
	Assay drift	469
	Low signal level	471
	Low binding in a competitive immunoassay	472

Low binding in an immunometric assay	474
Increase in binding in a competitive immunoassay	476
Reduction in ED ₅₀ (estimated dose at 50% of binding at zero concentration) competitive immunoassays only	477
Increase in ED ₅₀ (estimated dose at 50% of binding at zero concentration) competitive immunoassays only	478
High nonspecific binding	480
Poor linearity of dilution	481
Unexpected or inconsistent clinical classification	482
Apparent shift in reference interval (normal range)	485
Negative patient sample concentrations	487
Poor recovery	489
Poor assay sensitivity	491
Poor correlation between two immunoassays	493

PART 4 APPLICATIONS

52	Thyroid <i>Rhys John, Carole A. Spencer, Nic Christofides and David Wild</i>	497
	Normal thyroid function	497
	Clinical disorders	498
	Hypothyroidism (thyroid hormone deficiency)	498
	Hyperthyroidism	498
	Nontoxic goiter	499
	Nonthyroidal illness/sick euthyroid syndrome	499
	L-Thyroxine replacement therapy	500
	Endogenous antibodies to T ₃ and T ₄	500
	Familial dysalbuminemic hyperthyroxinemia	500
	Analytes	500
	Thyrotropin	500
	Thyroxine	502
	T ₃ or T uptake and calculation of free thyroxine index	503
	Free T ₄	505
	Triiodothyronine	509
	Free T ₃	511
	Thyroxine-binding globulin	514
	Thyrotropin receptor antibodies	516
	Thyroid peroxidase antibodies	516
	Thyroglobulin antibodies	517
	Thyroglobulin	518
	Thyroid testing strategies	518
53	The Adrenal Cortex <i>Sami Medbak</i>	521
	Normal adrenocortical function	521
	Clinical disorders	521
	Hypercortisolemia	521
	Hypercortisolemia	522
	Analytes	523
	Cortisol	523
	Adrenocorticotrophic Hormone (ACTH)	525
	Management of patients with cushing's syndrome	527
	Pre-admission	527
	Admission to endocrine ward (e.g. on Monday)	527
54	Bone Metabolism <i>Kay W. Colston and John C. Stevenson</i>	529
	Normal calcium metabolism	529
	Clinical disorders	529

	Hypercalcemia	529
	Parathyroid disorders	530
	Hypocalcemia	531
	Vitamin D disorders	531
	Medullary carcinoma of the thyroid	532
	Paget's disease	532
	Osteoporosis	532
	Analytes	532
	Vitamin D metabolites: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D	532
	Parathyroid hormone	535
	Parathyroid hormone-related protein	536
	Calcitonin	536
	Biochemical markers of bone turnover	537
	Markers of bone formation	537
	Markers of bone resorption	538
	Serum tartrate resistant acid phosphatase (TRAP)	540
55	Infertility <i>Michael J. Wheeler</i>	541
	Clinical disorders	542
	Primary hypogonadism in the female	542
	Secondary hypogonadism in the female	543
	Infertility and normal menstrual function	543
	Primary hypogonadism in the male	543
	Secondary hypogonadism in the male	543
	Impaired sperm transport and sperm viability	544
	Analytes	544
	Luteinizing hormone (Lutropin)	544
	Follicle-stimulating hormone (Follitropin)	546
	Prolactin	546
	Inhibin	548
	Estradiol	548
	Progesterone	549
	Testosterone	550
	Dihydrotestosterone	552
	Test strategy for infertility in women	553
56	In Vitro Fertilization and Embryo Transfer (IVF-ET) <i>August C. Olivar</i>	555
	Stage I: Induction of ovulation	555
	Stage II: Oocyte retrieval	556
	Stage III: Oocyte insemination and incubation	556
	Stage IV: Embryo transfer	556
	Other assisted reproductive technology procedures	556
	Gamete intra-fallopian tube transfer (GIFT)	556
	Zygote intra-fallopian transfer (ZIFT)	557
	Micromanipulation of gametes	557
	Assisted hatching	557
	Intra-cytoplasmic sperm injection (ICSI)	557
	Analytes	558
	Estradiol	558
57	Hirsutism and Virilization in the Female <i>Michael J. Wheeler</i>	561
	Clinical disorders	561
	Polycystic ovarian syndrome	561
	Idiopathic hirsutism	562
	Androgen-secreting tumors of the ovary	562
	Congenital adrenal hyperplasia	562

	Cushing's's syndrome	563
	Analytes	564
	Luteinizing hormone and follicle-stimulating hormone	564
	Testosterone	564
	Sex hormone-binding globulin	565
	Free testosterone	566
	Androstenedione	567
	Dehydroepiandrosterone sulfate (DHEAS)	568
	17 α -Hydroxyprogesterone	569
	Dihydrotestosterone	570
	Androstane diols and their glucuronides	570
58	Pregnancy <i>Tim Chard</i>	572
	Clinical disorders	573
	Detection of early pregnancy	573
	Threatened abortion	573
	Ectopic pregnancy	573
	Chromosome defects of the fetus	573
	Neural tube defects of the fetus (NTD)	574
	Premature labor	574
	Placental insufficiency	574
	Pre-eclampsia	574
	Miscellaneous disorders	575
	Analytes	575
	Alphafetoprotein	575
	Human chorionic gonadotropin	578
	Estriol	580
	Pregnancy-associated plasma protein-A	581
	Other analytes	582
	Screening for Down's Syndrome	583
59	Growth and Growth Hormone Deficiency <i>Michael Preece and Jane Pringle</i>	585
	Normal childhood growth	585
	Clinical disorders	586
	Growth hormone deficiency or insufficiency	586
	Growth hormone resistance	586
	Excessive growth hormone secretion	586
	Analytes	586
	Growth hormone	586
	Growth hormone binding protein	588
	Insulin-like growth factors: IGF-I (Somatomedin C) and IGF-II	588
	Insulin-like growth factor binding proteins	559
	General strategy	589
60	Diabetes Mellitus <i>Penny Clark and David Bates</i>	591
	Introduction	591
	Analytes	592
	Insulin, proinsulin(s) and C-peptide	592
	Glycohemoglobin (GHb)	596
	Other glycosylated proteins	599
	Microalbumin	600
	Immunological and other assays	601
61	Hematology <i>Derek Dawson and Harry Waters</i>	606
	Normal blood function	606
	Clinical disorders	607
	Anemia	607

Iron overload and hemochromatosis	607
Leukemia and Lymphoma	607
Hemostatic disorders	607
Analytes	607
Vitamin B ₁₂ and Folate	607
Intrinsic factor antibody	612
Ferritin	612
Transferrin	614
Transferrin receptors	615
Erythropoietin	616
Leukemia and Lymphoma	617
Leukemia and Lymphoma analytes	617
Hemostasis and Thrombosis	617
Hemostasis and Thrombosis analytes	617
Tests for platelet hypercoagulability	618
β-Thromboglobulin	618
Platelet factor 4	619
Thromboxane B ₂	619
Coagulation factors	619
Fibrinogen	619
Proteins C and S, and resistance to activated protein C	620
Anti-thrombin III	620
Heparin cofactor II	620
Plasminogen	621
Tissue plasminogen activator	621
Plasminogen activator inhibitor (PAI-1)	621
Fibrinogen/Fibrin degradation products	621
D-Dimer test	621
62 Cardiac Markers Alan H. B. Wu	623
Normal heart function	623
Clinical disorders	623
Coronary artery disease	623
Heart failure (HF)	625
Hypertension	625
Analytes	625
Creatine kinase and the MB isoenzyme	625
Myoglobin	626
Cardiac troponin (T and I)	627
Fatty acid binding protein (FABP) and carbonic anhydrase III isoenzyme (CAIII)	628
Apolipoproteins AI, AII and B	629
Lipoprotein (A)	629
Homocysteine	630
B-type natriuretic peptide (BNP)	631
Plasma renin	631
Plasminogen activators and inhibitors	633
63 Cancer Markers Mavanur R. Suresh	635
Introduction	635
History and classification	638
Nomenclature and idiosyncracies of glycoprotein tumor antigens	639
Analytes	640
Carcino-embryonic antigen	640
Alphafetoprotein	642
Carbohydrate antigen 19-9 (sialyl Lewis ^x)	643
Cancer antigen 125	644
Cancer antigen 15-3	646

188	Estrogen receptor and progesterone receptor	647
189	Fecal occult blood	648
190	Prostate-specific antigen	649
191	Prostatic acid phosphatase	650
192	β_2 -microglobulin	651
193	Neuron-specific enolase	652
194	Carbohydrate antigen 50	653
195	Squamous cell carcinoma antigen	653
196	Tissue polypeptide antigen, tissue polypeptide-specific antigen and cyfra 21-1	654
197	Placental alkaline phosphatase	655
198	Human chorionic gonadotropin	656
199	Cathepsin D	656
200	Interleukin-2 receptor	656
201	C-erb B-2 (Her-2/neu) oncoprotein	657
202	P53	657
203	Bladder tumor antigen	658
204	Immunochromatography assays for tumor markers	659
205	Novel experimental and other markers	659
206	Cancer antigen 195 (CA-195)	659
207	Tumor-associated glycoprotein 72.4 (TAG 72.4)	659
208	S-100 antigen	660
209	Sialyl Lewis (SLX ₋₁)	660
210	Mucin-like carcinoma-associated antigen (MCA)	660
211	Cancer-associated antigen 549 (CA-549)	660
212	Bone alkaline phosphatase	660
213	B/T gene rearrangement test	660
214	BRCA1 and BRCA2	660
215	P21 or RAS	660
216	DR-70	661
217	90K/MAC-2 BP	661
218	Bcl-2	661
219	NMP-22	661
220	NMP assays	661
221	TAG-12	661
222	CA1-18	661
223	Angiogenic factors	661
224	Chromogranin A	662
225	Telomerase	662
64	Allergy Lars Yman	664
	Allergic disease	664
	Diagnosis and therapy	664
	Allergens	664
	Analytes	666
	Total serum IgE	666
	Allergen-specific IgE antibody	667
	IgG antibody assays	673
	IgG antibody assay	674
	Markers of cell activation	674
	Standardization and evaluation	674
	Quantitative measurement of allergen-specific IgE antibodies	674
	Reference values	675
	Quality control	676
	Clinical applications	676
	Diagnosis of atopic disease and identification of offending allergen	676
	Prediction and monitoring of the development of allergic disease	676

65	Autoimmune Disease <i>David F. Keren</i>	681
	Analytes	682
	Anti-nuclear antibodies	682
	Anti-double-stranded (DS) DNA	683
	Anti-SM	685
	Anti-RNP	686
	Anti-SSA/RO	686
	Anti-SSB/LA	687
	Anti-histone	687
	Anti-DNP	688
	Anti-centromere	688
	Anti-SCL-70	689
	Rheumatoid factor	689
	Anti-neutrophil cytoplasmic antibodies (C-ANCA, P-ANCA)	690
	Anti-glomerular basement membrane (GBM)	691
	Anti-Jo-1	691
	Anti-microsomal (thyroid peroxidase-TPO)	692
	Islet cell autoantibodies (ICA)	692
	Anti-adrenal cortical antibodies	692
	Anti-parietal cell antibodies (PCA)	693
	Anti-mitochondrial antibodies (AMA, or M2)	693
	Anti-smooth muscle antibodies (SMA)	694
	Anti-liver-kidney microsomal (LKM)	694
	IgA anti-endomysium, tissue transglutaminase	695
	IgG and IgA anti-gliadin	695
	Anti-acetylcholine receptor (AChR)	695
	Striational antibodies	696
	Calcium channel antibodies	696
	Anti-cardiolipin antibodies	697
66	Sexually Transmitted Diseases <i>Bruce J. Dille, Alan S. Armstrong and Isa K. Mushahwar</i>	700
	<i>Neisseria Gonorrhoeae</i>	700
	<i>Chlamydia trachomatis</i>	702
	<i>Trichomonas vaginalis</i>	705
	<i>Candida albicans</i> - vaginitis	706
	<i>Gardnerella vaginalis</i>	707
	Herpes simplex virus type 2	708
	Syphilis (<i>Treponema pallidum</i>)	711
67	Congenital Diseases of Microbiological Origin <i>Bruce J. Dille, John W. Safford Jr. and Isa K. Mushahwar</i>	712
	Cytomegalovirus	712
	Rubella virus	714
	<i>Toxoplasma gondii</i>	716
	Parovirus B19	717
	Group B Streptococci	719
68	Hepatitis <i>Isa K. Mushahwar</i>	722
	Hepatitis A virus, anti-HAV IgM, anti-HAV IgG	722
	Hepatitis B virus, HBsAg, HBcAg, HBeAg, anti-HBs, anti-HBc, anti-HBc IgM, anti-HBe	724
	Hepatitis C virus	729
	Hepatitis D virus	731
	Hepatitis E virus	732
	GB viruses	734
	GB virus C	735

69	Human Retroviruses <i>George J. Dawson and Isa K. Mushahwar</i>	737
	Etiologic agents	737
	HTLV-I/II	737
	HIV-1/-2	740
70	Dengue Virus Infections <i>Bruce J. Dille and Isa K. Mushahwar</i>	745
71	Miscellaneous Diseases of Microbiological Origin <i>Bruce J. Dille and ISA K. Mushahwar</i>	
	Herpes simplex virus type 1	750
	Epstein-Barr virus	752
	Chagas' disease	754
	<i>Candida albicans</i> - invasive candidiasis	755
	<i>Borrelia burgorferi</i>	756
	<i>Helicobacter pylori</i>	758
	Group A streptococcus	759
	Human herpesvirus 6	760
	Human herpesvirus 8 (Kaposi's sarcoma herpesvirus)	762
72	Therapeutic Drug Monitoring (TDM) <i>Philip A. Routledge and Alan D. Hutchings</i>	763
	Introduction	763
	Assay technology	763
	Measurement of free drug concentration	764
	Practical aspects of TDM	765
	Antiarrhythmic drugs	765
	Acecaide (<i>N</i> -acetylprocainamide)	765
	Disopyramide	766
	Lidocaine	766
	Procainamide	767
	Propranolol	767
	Quinidine	768
	Amiodarone	768
	Flecainide	769
	Antibiotics	769
	Amikacin	769
	Kanamycin	770
	Gentamicin	771
	Tobramycin	771
	Netilmicin	771
	Chloramphenicol	772
	Vancomycin	773
	Anticonvulsants	773
	Phenytoin	773
	Phenobarbital (phenobarbitone)	774
	Primidone	774
	Carbamazepine	775
	Valproic acid	775
	Ethosuximide	776
	Chemotherapeutic agents	776
	Methotrexate	776
	Miscellaneous	777
	Acetaminophen (paracetamol)	777
	Tricyclic antidepressants	777
	Cyclosporin	778
	Digoxin	778
	Digitoxin	779
	Theophylline	779

73	Drugs of Abuse <i>Brian Widdop</i>	781
	Applications	781
	Drug dependence treatment centers	781
	Psychiatric clinics	782
	Medical-legal applications	782
	Drug abuse in the workplace	782
	Immunoassays for drugs of abuse	782
	Amphetamine	783
	Methamphetamine	784
	Methylenedioxyamphetamine (MDA)	784
	Methylenedioxymethamphetamine (MDMA)	784
	Barbiturates	788
	Benzodiazepines	790
	Cannabis	793
	Cocaine	796
	Fentanyl	799
	Lysergic acid diethylamide	800
	Methadone	802
	Opiates	805
	Phencyclidine	808
	Propoxyphene	810
	Legal addictive substances	811
	Alcohol (ethyl alcohol) and the use of carbohydrate-deficient transferrin (CDT)	811
	Nicotine and the use of cotinine	812
	Steroid abuse in sport*	812
	Anabolic androgenic steroids (AAS)	812
	Rapid immunoassay tests for drugs of abuse	814
74	Immunoassay Applications in Life-science <i>Michael J. O'Sullivan, Steve Capper, Jeffrey K. Horton, John Whateley and Peter Baxendale</i>	817
	Assay technology	820
	Tritium radioimmunoassays	820
	Iodine-125 radioimmunoassays	820
	Scintillation proximity assay®	820
	Enzyme immunoassays (colorimetric)	822
	Enhanced luminescence immunoassays	823
	Immunofiltration screening assays	824
	Analytes	826
	Prostaglandins	826
	Leukotrienes	828
	Rat hormone assays	828
	Steroids	831
	Cytochrome P450	831
	Cytokines	832
	Adhesion molecules	837
	Signal transduction assays	838
	Cell proliferation immunoassay	840
	Matrix metalloproteinases (MMPs)	840
	Cardiovascular peptide	844
75	Immunoassay Applications in Veterinary Diagnostics <i>Erwin Workman</i>	846
	Introduction	846
	Infectious disease diagnosis/assessment of immune status	846
	Feline	846
	Canine	849
	Porcine	852
	Equine	854

Bovine	855
Avian	859
Murine	862
Assessment of reproductive/metabolic status	863
Feline/Canine	863
Equine	864
Bovine	864
Conclusion	865